Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of S086 added to amlodipine in primary hypertension inadequately controlled with amlodipine alone
CTR20232252Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Sep 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of S086 and amlodipine in essential hypertension (2 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Change from baseline in mean sitting systolic blood pressure. Started Sep 2023; status: completed.
02
Drugs
S086amlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20232252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232252.